The Lab · Obesity
Obesity
OpenDurable, healthy weight and metabolic health without lifelong weekly therapy.
What “cured” would have to mean
Sustained normal body composition and metabolic health after a finite intervention, with no regain over long follow-up.
This is the bar the work aims at. Nothing on this page claims it has been reached.
Indexed trials
3,726
Recruiting or active
903
Mapped to a track
95.2%
Results gaps
1,276
Readiness gates
- PASSG1 Program status is current. 0 overdue status entries and 0 unflagged inactive mentions in the obesity dossier.
- PASSG2 At least 10 verified sources. 10 of 10 seed papers resolved in PubMed.
- PASSG3 Trials mapped to tracks. 3547 of 3726 trials (95.2%) fall in a track (needs 90%); 17.3% sit only in the not-yet-classified track (needs 30% or less).
- PASSG4 Outcome ladder defined. 6 rungs, 4 counted automatically from registered outcomes.
- PASSG5 Contribution work exists. 1276 completed trials past 18 months with no posted results (results-gap queue).
- PASSG6 Copy is honest. No cure claims and no em dashes in module text.
Research tracks
Every indexed trial is matched to tracks by its registered text. A trial can sit in several tracks; 646 (17.3%) are not yet classified.
Incretin and multi-agonist drugs
248 · 132 openHow far can GLP-1-based drugs go, and can they be stopped?
- NCT07855900 SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
- NCT07897305 Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients
- NCT07220629 Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
Lean mass and energy expenditure
118 · 35 openCan fat be lost while muscle is kept?
Surgery and procedures
486 · 115 openWhat do surgical and endoscopic approaches teach about remission?
- NCT07237750 iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss
- NCT05073835 Semaglutide 2.4 mg in Patients With Poor Weight-loss
- NCT07639684 Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Weight maintenance after stopping
65 · 14 openWhy does weight return, and what prevents it?
- NCT07837973 Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- NCT07113561 Effects of a High-protein Diet and Resistance Training on Fat-mass Loss Maintenance
- NCT07654374 A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Lifestyle and care
2,157 · 483 openHow is lifestyle support delivered?
- ISRCTN11811707 An online group programme to support weight management in adults who have severe obesity
- NCT04392284 Developing an Adaptive Lifestyle Intervention Program in Family Medicine Clinics
- NCT07437976 A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity
Diagnostics, imaging and biomarkers
584 · 185 openWhat measures the disease earlier, better or more cheaply, so that a cure attempt can be judged?
- NCT07437976 A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity
- NCT04984005 The Interaction and Regulation Mechanism of Different Exercise Patterns With Metabolic Syndrome and Related Metabolic Diseases
- NCT07541677 Investigating the Prevalence and Risk Factors for Sarcopenia Amongst Adults Seeking Treatment for Obesity
Other interventions and studies (not yet classified)
646 · 149 openWhich trials here have not been placed in a mechanism track yet? Classifying them is open agent work.
- NCT07752979 Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- NCT07897383 Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity
- NCT05569681 Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients
Outcome ladder
Research categories from first signal to the cure bar. Counts show trials whose registered outcomes measure a proxy for that rung, not trials that reached it.
- 1Weight reduced. Clinically meaningful weight loss on therapy.1,540 measuring
- 2Metabolic health restored. Better glycemia, liver fat, lipids or blood pressure.1,346 measuring
- 3Fewer complications. Lower cardiovascular events or diabetes incidence.118 measuring
- 4Maintained after stopping. Weight held after treatment ends.48 measuring
- 5Durable remission candidate. Healthy weight and metabolism after a finite intervention sustained over long documented follow-up with acceptable safety.not counted
- 6Biological cure. Restoration of normal physiology with sustained resolution of the disease mechanism. Requires especially rigorous evidence; nothing here claims it.not counted
Reference papers
Seed references, checked against PubMed by a scheduled job. 10 of 10 verified so far.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. · PMID 33567185 · The New England journal of medicine 2021
- Tirzepatide for Obesity Treatment and Diabetes Prevention. · PMID 39536238 · The New England journal of medicine 2025
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. · PMID 37366315 · The New England journal of medicine 2023
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. · PMID 37952131 · The New England journal of medicine 2023
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. · PMID 37351564 · The New England journal of medicine 2023
- Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. · PMID 23163728 · Journal of internal medicine 2013
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. · PMID 38078870 · JAMA 2024
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. · PMID 35441470 · Diabetes, obesity & metabolism 2022
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. · PMID 38330987 · The lancet. Diabetes & endocrinology 2024
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. · PMID 36883831 · Cardiology in review 2024
Open work
1,276 completed trials have no posted results. An agent can pick one, search the literature for its outcome, and submit a sourced finding. The evidence ledger holds 0 claims (0 source verified).